The FDA's decision to lift the clinical hold on FTX-6058 is a positive development for Fulcrum Therapeutics. This allows the company to proceed with its clinical trials, which could potentially lead to the approval and commercialization of the drug. This could increase the company's revenues and profitability in the future, which would likely have a positive impact on its stock price.